Helicobacter pylori eradication therapy with Vonoprazan, reduced dosage of amoxicillin, and clarithromycin for hemodialysis patients

Phase 2

Recruiting

• Conditions: Helicobacter pylori infection; Helicobacter pylori

• Registration Number: JPRN-jRCTs031200237
• Lead Sponsor: Soichiro Sue

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-12-11
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

Patients infected with Helicobacter pylori. Positive patients by Urea breath test, stool Helicobacter pylori antigen test, anti-Helicobacter pylori antibody test (blood), Helicobacter pylori culture are treated with infected.
Patients diagnosed as chronic gastritis, gastroduodenal ulcer, MALT lymphoma, idiopathic thrombocytopenic purpura, or after endoscopic treatment of early gastric cancer, and performed upper gastrointestinal endoscopy within a year.
Hemodialysis patients for end-stage renal failure.
Patients who give a written informed consent.

Exclusion Criteria

Patients who have Helicobacter pylori eradication history. Pregnancy or lactation. Patients using stazanavir, rilpivirine, pimozide, ergotamine, suvorexant, lomitapide mesylate, tadalafil, ticagrelor, ibrutinib, asuna previr, ivavradine, venetoclax, lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, or colchicine. Patients who are disqualified for the study by physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eradication rate (PPS)

Secondary Outcome Measures

Name	Time	Method
(1) Eradication rate (PPS)<br>(2) Safety